Search results
15 wrz 2022 · Incidence, diagnostic methods, and evolution of left ventricular thrombus in patients with anterior myocardial infarction and low left ventricular ejection fraction: a prospective multicenter study. Am Heart J. 2015;170:256–262. doi: 10.1016/j.ahj.2015.04.029
- View EPUB
PK u!3Yoa«, mimetypeapplication/epub+zipPK u!3Y...
- Linda S. Williams
Many diseases with specific indications for specific...
- PDF/Epub
PK u!3Yoa«, mimetypeapplication/epub+zipPK u!3Y...
- Trial
Background—The Randomized Evaluation of Long-term...
- Results From the GEIST
Left ventricular (LV) thrombus formation is a well‐known...
- Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome
Objective: Takotsubo syndrome (TTS) is characterized by...
- Stroke
National Center. 7272 Greenville Ave.Dallas, TX 75231....
- Peripartum Cardiomyopathy
Peripartum cardiomyopathy is a potentially life-threatening...
- View EPUB
Left ventricular (LV) thrombus is a feared complication of LV dysfunction associated with high rates of systemic embolism, morbidity, and mortality. Traditionally, LV thrombus has been associated with acute myocardial infarction (MI).
23 wrz 2022 · On the basis of limited data, patients with nonischemic cardiomyopathy with LV thrombus should be treated with OAC for at least 3–6 months, with discontinuation if LV ejection fraction improves to >35% (assuming resolution of the LV thrombus) or if major bleeding occurs.
27 cze 2023 · Management Options for LVT Persistence. In large observational studies, the rate of thrombus resolution at 6 months ranged from more than 80% to as low as 30%. 26,40 In the setting of persistent LVT, most studies continued anticoagulation or switched to a different anticoagulant (Table 2).
Left ventricular thrombus (LVT) is a serious complication of acute myocardial infarction (MI) and also non-ischemic cardiomyopathies. We performed a narrative literature review, manual-search of reference lists of included articles and relevant reviews.
When asked what proportion of LVT found on echo would be verified on CMR, 51% stated <50%, 20% 50–75% and 29% >75%. Regarding frequency of cases seen annually, 41% reported seeing <20 cases and 8% >60 cases. For treatment, 66% preferred VKA whilst 30% used a DOAC (Figure 1).
Management of LV thrombus (LVT) is challenging and crucial to prevent the potential development of thromboembolic complications such as stroke. Anticoagulation with warfarin is recommended for the prevention of thromboembolic events, but novel oral anticoagulants (NOAC) have been used in clinical practice without supporting evidence.
